Comparison of Safety and Efficacy between Venetoclax Combined with CAG (cytarabine, aclarubicin, G-CSF) Regimen and CAG Regimen Alone in Patients with Relapsed or Refractory Acute Myeloid Leukemia

被引：2

作者：

Yu, Wen-Jing ^{[1
]}

Wu, Ying ^{[1
]}

Chen, Qi ^{[1
]}

Zhu, Xiaolu ^{[1
]}

Pei, Xu-Ying ^{[1
]}

Jia, Jin-Song ^{[2
]}

Wang, Jing ^{[1
]}

Zhao, Xiao-Su ^{[1
]}

Chang, Ying-Jun ^{[1
]}

Lai, Yue-Yun ^{[1
]}

Shi, Hong-Xia ^{[1
]}

Ruan, Guo-Rui ^{[1
]}

Qin, Ya-Zhen ^{[1
]}

Liu, Xiao-Hong ^{[1
]}

Huang, Xiao Jun ^{[1
,3
]}

Jiang, Hao ^{[1
]}

机构：

[1] Peking Univ, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Inst Hematol, Natl Clin Res Ctr Hematol Dis,Peoples Hosp, Beijing, Peoples R China

[2] Peking Univ, Inst Hematol, Peoples Hosp, Beijing, Peoples R China

[3] Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-184665

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[31] Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia
Li, Jianyong
Chen, Yaoyu
Zhu, Yu
Zhou, Jianfeng
Xu, Yanli
Li, Yan
Yu, Kang
Pan, Ling
Wang, Jianmin
Ding, Jiahua
Gu, Jian
Zhou, Shanhua
Shi, Jinning
Hong, Ming
Xu, Ji
Pan, Liangqin
Duan, Limin
Zhang, Run
Zhang, Sujiang
Zhu, Huayuan
Lu, Hua
Liu, Peng
Qiu, Hongxia
Wu, Hanxin
Qian, Sixuan
ONCOTARGET, 2015, 6 (08) : 6448 - 6458
[32] Efficacy and safety of G-CSF, low-dose cytarabine and aclarubicin in combination with L-asparaginase, prednisone in the treatment of refractory or relapsed acute lymphoblastic leukemia
Zhou, Keshu
Song, Yongping
Zhang, Yanli
Wei, Xudong
Fu, Yuewen
Yu, Fengkuan
Zhou, Hu
Liu, Xinjian
Zhou, Jian
Fang, Baijun
LEUKEMIA RESEARCH, 2017, 62 : 29 - 33
[33] Venetoclax combined with hypomethylating agents and the CAG regimen in relapsed/refractory AML: a single-center clinical trial
Liu, Yifan
Li, Yanfen
Zhang, Ran
Yu, Zhangyu
Jing, Yu
FRONTIERS IN IMMUNOLOGY, 2023, 14
[34] Etoposide and cytarabine as an effective and safe cytoreductive regimen for relapsed or refractory acute myeloid leukemia
Nair, G.
Karmali, R.
Gregory, S. A.
Shammo, J. M.
Fung, H. C.
Jimenez, A.
Venugopal, P.
Larson, M. L.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[35] EFFICACY AND SAFETY OF ADJUSTED CAG IN COMBINATION WITH DECITABINE IN NEWLY DIAGNOSED OR REFRACTORY/RELAPSED ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA
Chen, B.
Guan, C.
xShao
Xu, P.
Yang, Y.
Zhou, R.
Xu, J.
Li, J.
Xu, Y.
xXu
Zhou, M.
Xie, T.
xWang
Ouyang, J.
HAEMATOLOGICA, 2016, 101 : 678 - 678
[36] Outcomes of refractory or relapsed DNMT3A+ cytogenetically normal acute myeloid leukemia patients receiving the therapy including decitabine conbined with CAG or CAG-like regimen
徐妍珺
ChinaMedicalAbstracts(InternalMedicine), 2016, 33 (01) : 54 - 55
[37] Decitabine combined with low-dose cytarabine, aclarubicin and rhG-CSF regimen may be a potential alternative for relapsed/refractory acute myeloid leukemia: A single-center study
Fu, Yu
Su, Long
Li, Yuying
Tan, Yehui
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2023,
[38] Venetoclax added to CLAG regimen might improve the outcome of patients with relapsed/refractory acute myeloid leukemia
Zhang, Yu
Yin, Zhao
Yao, Zurong
Xu, Dan
Jiang, Xuejie
Nie, Xiaqi
Chen, Dandan
Zhou, Hongsheng
Shi, Pengcheng
Liu, Hui
Liu, Qifa
Yu, Guopan
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2025, 16
[39] Efficacy and safety of the combination of decitabine and CHAG priming regimen in the relapsed or refractory acute myeloid leukemia
Wu, Yan
Liang, Jinping
Mi, Ruihua
Wang, Lin
Chen, Lin
Wei, Xudong
SCIENTIFIC REPORTS, 2024, 14 (01):
[40] Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia
Liu, Limin
Qu, Qi
Jiao, Wenjing
Zhang, Yanming
Li, Xiaoli
Ding, Chao
Wu, Depei
LEUKEMIA RESEARCH, 2015, 39 (08) : 805 - 811

← 1 2 3 4 5 →